Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company dedicated to advancing both innovative cell therapy platforms and a pipeline of generic and branded pharmaceutical products, primarily targeting cancer patients. Its leading oncology assets include CD38-GEAR-NK, a Vy-Gen drug candidate engineered to combat CD38-positive cancers such as multiple myeloma, chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). Alongside this, the company offers CD38-Diagnostic, an in vitro screening tool designed to identify cancer patients who are most likely to respond favorably to targeted anti-CD38 monoclonal antibody treatments. Beyond its internal pipeline, Coeptis also engages in strategic partnerships. It collaborates with Statera BioPharma on the development and commercialization of STAT-201 for Crohn's disease. Additionally, it holds co-development and ownership rights for CPT60621, a potential therapy for Parkinson's Disease, through a collaboration with Vici Health Sciences, LLC. Established in 2017, the company maintains its headquarters in Wexford, Pennsylvania.
